Table 4. Clinical outcomes of patients with BRAF^non-V600 mutations treated with a selective BRAF inhibitor and/or a MEK inhibitor.

Patient #	Age	Gender	BRAFNon-V600 mutation	Stage	Treatment	Response	PFS (Months)	OS (Months)
1	84	M	G469R	M1c	Vemurafenib	NE	NE	NE
2	35	M	K601E	M1c	Vemurafenib	NE	NE	NE
3	85	M	G469R	M1a	Vemurafenib	NE	NE	NE
4	56	F	L597R	M1c	Vemurafenib	PD	4.3	11.2
5	51	M	S467L	M1c	Vemurafenib	PD	1.9	5.6
6	69	F	G466V	M1c	Vemurafenib	PD	0.9	3.7
7	44	M	L597Q	M1c	Vemurafenib	PD	2.0	5.4
8	70	M	G469R	M1c	Vemurafenib	PD	3.5	9.1
9	74	M	G466E	M1c	Vemurafenib	PD	1.9	+ 30.6
10	52	M	K601E	M1c	Dabrafenib	PD	0.7	+ 64.5
11	36	M	K601E	M1c	Dabrafenib and trametinib	PD	2.0	+ 4.5
12	57	F	L597R	M1c	Trametinib	PD	1.7	4.8
13	76	M	G466E	M1c	Trametinib	PD	1.5	5.2
14	66	M	G469E	M1c	Trametinib	PD	1.3	7.1

PFS, progression free survival; OS, overall survival; PD, progressive disease; NE, not evaluable.